| MNST |
Report |
Net sales |
BEAT |
pred ~$2.51B vs. cons $2.43B |
MEDIUM |
| MNST |
Report |
Diluted EPS |
BEAT |
pred ~$0.61 vs. cons $0.58 |
MEDIUM |
| MNST |
Report |
Gross margin |
IN-LINE |
pred ~54.9% vs. cons 54.7% |
MEDIUM |
| MNST |
Guide |
3Q26 net-sales trajectory / implied revenue outlook |
BETTER |
guide ~$2.50B vs. cons $2.44B (3Q26) |
MEDIUM |
| MNST |
Guide |
2H26 gross-margin commentary |
LOWER |
guide ~54.6% vs. cons 54.8% (2H26) |
MEDIUM |
| MNST |
Guide |
FY26 diluted-EPS implication |
BETTER |
guide ~$2.36 vs. cons $2.31 (FY26) |
LOW |
| MNST |
Return |
Day-1 residual (stock − beta × S&P 500) |
+4.0% |
— |
MEDIUM |
| MNST |
Return |
5-day cumulative residual |
+5.5% (FOLLOW-THROUGH) |
A ~$0.03 EPS beat and ~$80M revenue beat should lift FY26 implied EPS to ~$2.36 versus ~$2.31 consensus, while sustained international growth offsets only modest 2H gross-margin-rate pressure; positive out-period revisions support follow-through. |
MEDIUM |